

Applied Pharmacoeconomic and Outcomes Research Forum

June 8th 2009





- 1. AMCP Dossiers: Useful for Decision Making or Not? A Debate
- 2. Biologics: Drawing (or Crossing) the line of Cost vs. Benefit: A Case in Oncology
- 3. Quality Adjusted Life Years (QALY's) for Decision Making: Views from Canada & the US
- 4. Using Large Databases to Inform Decision Making: Experience in Three Health Care Systems
- 5. Real World Data for Decision Making: Moving Beyond Clinical Trials
- 6. Pharmacoeconomics of Pharmacogenomics





Participants

Aetna Aequitas Amgen Amylin Bristol Meyers Squibb E.B.D. Group Kaiser Permanente MedImpact Healthcare Systems Medi-Cal Dept Health Services Miller Pharma Consulting Milliman **Novartis**

Ortho-McNeil Janssen Partnership for Health Analytic Research, LLC Pfizer Prescription Solutions Sharp Health Touro University UCSD Medical Center UCSD School of Medicine UCSD School of Pharmacy USC School of Pharmacy USSF School of Pharmacy

Steering Committee

Charles Daniels, R.Ph., Ph.D. UCSD Healthcare Department of Pharmacy

Ted Ganiats, MD UCSD School of Medicine Darlene Fujimoto, Pharm.D Biogen-Idec (formerly)

Jan D. Hirsch, R.Ph., Ph.D. UCSD, Skaggs School of Pharmacy & Pharmaceutical Sciences

Mirta Millares, Pharm.D., FCSHP, FASHP Kaiser Permanente – CA Regions Anthony P. Morreale, Pharm.D., MBA, BCPS VA San Diego Healthcare System

Robert Schoenhaus, Pharm.D. Sharp Healthcare

Sponsors ·	- Thanks!
LLERGAN	biogen idec



Agenda

Moderator: Mirta Millares, PharmD, FCSHP, FASHP Kaiser Permanente

Introduction to Pharmacogenomics

Genetic Technology: Practical Issues for Health Plans

BREAK

Impact of Pharmacogenomics on Drug Development & Commercialization: An International Perspective

Panel Q & A/Discussion Participant Consensus Grace Kuo, PharmD, MPH

UCSD, Skaggs School of Pharmacy & Pharmaceutical Sciences

Jill Van Den Bos, MA Milliman

Dave W. Miller, PhD Miller Pharma Consulting